Corticosteroid pharmacokinetics in liver disease

Area of Science:

• Pharmacology
• Hepatology
• Clinical Medicine

Background:

• Corticosteroids, particularly prednisone, are frequently used for chronic active liver disease.
• Understanding prednisone pharmacokinetics is crucial for optimizing treatment.
• Prednisone's active form, prednisolone, is key to its therapeutic effect.

Purpose of the Study:

• To investigate the pharmacokinetics of prednisone in patients with liver disease.
• To determine the absorption, conversion, and bioavailability of prednisone and prednisolone.
• To identify factors influencing prednisone's side effect profile in liver disease patients.

Main Methods:

• Pharmacokinetic analysis of prednisone and prednisolone.
• Comparison of oral versus intravenous administration.
• Assessment of drug bioavailability and protein binding.
• Correlation of serum albumin levels with drug clearance and side effects.

Main Results:

• Prednisone is well-absorbed orally and converted to prednisolone in patients with liver disease.
• Oral prednisone bioavailability is approximately 100% compared to intravenous dosing.
• Patients with hypoalbuminemia experience decreased protein binding and delayed clearance of prednisolone.
• Hypoalbuminemia is linked to an increased risk of prednisone-related side effects.

Conclusions:

• Prednisone is an effective treatment for chronic active liver disease with predictable pharmacokinetics.
• Liver disease patients, especially those with hypoalbuminemia, require careful monitoring and potential dosage modification.
• Serum albumin levels are a critical factor in managing prednisone therapy to mitigate adverse events.